Study of 18F-Thretide PET/CT in Patients With Prostate Cancer

Summary

This study evaluates the diagnostic performance and safety of 18F-Thretide PET/CT in patients with biopsy proven prostate cancer who has no any form of therapy against prostate caner or suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.

Timeline

Start

2022-08-20

Primary completion

2023-03-31

Completion

2023-09-01

Publications

• Zang J, Yang Y, Chen S, Wang C, Chen S, Hu S, Cai H, Li X, Xu N, Chen X, Zhang J, Miao W. Diagnostic Performance of [18F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard. J Nucl Med. 2024 Jul 1;65(7):1021-1026. doi: 10.2967/jnumed.123.266940.

Drugs

Indications